ClinicalTrials.gg
Active, not recruitingNCT07400107AMAZE 8Updated Nov 10, 2026

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

A Phase 3 interventional study of NNC0487-0111 and Semaglutide in Obesity, Overweight and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Active, not recruiting at 122 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Updated Nov 10, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
985
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.

Enrollment
4th of 24
985 · median 360
Started
2026
with 18 others
Phase 3
14 of 24
11 open now
Primary completion
2028-12
later than 14 of 19 live
Registered
6th of 24
by date
Lead sponsor
24 of 24
Novo Nordisk A/S

Among the 24 studies testing zenagamtide in Obesity, this one is the 4th largest by enrollment, is one of 19 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 14 of the 19 other live ones, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About zenagamtide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing zenagamtide in Obesity, or all of them as a file.
02

Study summary

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. Participant will receive 2 injections every week: an active medicine and a placebo, both taken as injections under the skin once a week. The placebo is a treatment with no active medicine in it and will be given to all participants. In addition to placebo, participants will receive either of the active medicine NNC0487-0111 (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator). Which treatment participants get is decided by chance.

03

Conditions studied

  • Obesity
  • Overweight
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female (sex at birth).
  • Age 18 years or above at the time of signing .
  • Diagnosed with type 2 diabetes mellitus ≥ 180 days before screening.
  • (HbA1c) 7-10 percentage (%) (53-86 millimole per mole [mmol/mol]) (both inclusive) as measured by the central laboratory at screening.
  • Treatment with lifestyle intervention, and/or 0-3 marketed oral antidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i), thiazolidinediones, or sulfonylureas (SU) as a single agent or in combination) according to local label. Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) before screening.

Key Exclusion Criteria:

  • Renal impairment with estimated (eGFR) \< 30 milliliter (mL)/ minute (min)/1.73 meter squared (m\^2) (2021 Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula), at screening.
  • Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8.
  • Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator.
  • Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
985 participants (actual)

Study arms

  • Experimental
    NNC0487-0111

    Participants will receive NNC0487-0111 and placebo matched to semaglutide subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: NNC0487-0111 · Drug: Placebo (matched to semaglutide)

  • Active comparator
    Semaglutide

    Participants will receive semaglutide and placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: Semaglutide · Drug: Placebo (matched to NNC0487-0111)

Interventions

  • NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • Semaglutide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • DrugPlacebo (matched to NNC0487-0111)

    Placebo matched to NNC0487-0111 will be administered subcutaneously using pre- filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • DrugPlacebo (matched to semaglutide)

    Placebo matched to semaglutide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

06

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured as percentage of body weight.

    Time frame: From baseline (week 0) to week 84

Secondary outcomes

  1. Change in waist circumference

    Measured as centimeter (cm).

    Time frame: From baseline (week 0) to week 84

  2. Change in systolic blood pressure (SBP)

    Measured as millimeter of mercury (mmHg).

    Time frame: From baseline (week 0) to week 84

  3. Change in body weight

    Measured as kilograms (kg).

    Time frame: From baseline (week 0) to week 84 and week 104

  4. Change in body mass index (BMI)

    Measured as kilograms per meter squared (kg/m\^2).

    Time frame: From baseline (week 0) to week 84 and week 104

  5. Number of participants with achievement of in haemoglobin A1c (HbA1c) < 7.0 percent (%) (yes/no)

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 84

  6. Number of participants with achievement of HbA1c ≤ 6.5% (yes/no)

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 84

  7. Number of participants with achievement of HbA1c < 5.7% (yes/no)

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 84

  8. Change in fasting plasma glucose (FPG) measured as millimole per liter (mmol/L)

    Measured as mmol/L.

    Time frame: From baseline (week 0) to week 84

  9. Change in FPG measured as milligrams per deciliter (mg/dL)

    Measured as mg/dL.

    Time frame: From baseline (week 0) to week 84

  10. Ratio to baseline: change in fasting insulin

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84

  11. Ratio to baseline: change in urinary albumin-to-creatinine ratio (UACR)

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84

  12. Change in diastolic blood pressure (DBP)

    Measured as mmHg.

    Time frame: From baseline (week 0) to week 84

  13. Ratio to baseline: change in total cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84

  14. Ratio to baseline: change in high-density lipoprotein (HDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84

  15. Ratio to baseline: change in low-density lipoprotein (LDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84

  16. Ratio to baseline: change in very low-density lipoprotein (VLDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84

  17. Ratio to baseline: change in non-HDL cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84

  18. Ratio to baseline: change in triglycerides

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84

  19. Ratio to baseline: change in high-sensitivity C-reactive protein (hsCRP)

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84

  20. Number of Treatment Emergent Adverse Events (TEAEs)

    Measured as events.

    Time frame: From baseline (week 0) to week 84 and week 109

  21. Number of Treatment Emergent Serious Adverse Events (TESAEs)

    Measured as events.

    Time frame: From baseline (week 0) to week 84 and week 109

  22. Number of TEAEs leading to permanent treatment discontinuation

    Measured as events.

    Time frame: From baseline (week 0) to week 84 and week 109

  23. Number of treatment-emergent clinically significant hypoglycaemic episodes (level 2) (< 3.0 millimole per liter [mmol/L] (54 milligrams per deciliter [mg/dL]), confirmed by a blood glucose (BG) meter)

    Measured as episodes.

    Time frame: From baseline (week 0) to week 84 and week 109

  24. Number of treatment-emergent severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as episodes.

    Time frame: From baseline (week 0) to week 84 and week 109

07

Study locations

122 sites

Showing the first 100 of 122 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 30 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2029 → Dec 2028, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartActual
May 20, 2026
Primary completionEst.
Dec 19, 2028
CompletionEst.
Dec 19, 2028was Jan 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Nov 10, 2026
Sites
20 sites added, 18 sites removed
Show 20 added (8 Poland, 6 Portugal, 2 India, 1 Germany, 1 Hungary, 1 Romania, 1 Turkey (Türkiye))
  • Zentrum für klinische Studien Südbrandenburg GmbH · Elsterwerda, Germany
  • Békés Vármegyei Központi Kórház · Gyula, Hungary
  • All India Institute of Medical Sciences (AIIMS), Raipur · Raipur, India
  • Osmania General Hospital · Hyderabad, India
  • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j. · Ruda Śląska, Poland
  • Serce Sp. z o.o. · Leszno, Poland
  • Przychodnie Grudziadz Sp. z o. o. · Grudziądz, Poland
  • Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j. · Legnica, Poland
  • Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski · Gorzów Wielkopolski, Poland
  • NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska · Bialystok, Poland
  • NZOZ Vita-Diabetica Malgorzata Buraczyk · Bialystok, Poland
  • Centrum Terapii Wspolczesnej - J.M. Jasnorzewska S.K.A. · Lodz, Poland
  • ULS Almada-Seixal E.P.E. - HGO_Serviço de Endocrinologia · Almada, Portugal
  • ULS De Braga, E.P.E. - Hospital de Braga_Centro Clínico Académico · Braga, Portugal
  • Hospital de Cascais_Serviço de Medicina Interna_Consultas Externas · Cascais, Portugal
  • ULS De São João, E.P.E. - Hospital de São João_Consulta Externa Endocrinologia · Porto, Portugal
  • ULS De Matosinhos, E.P.E - HPH_Serviço de Endocrinologia · Senhora Da Hora, Matosinhos, Portugal
  • Hospital da Luz Arrábida, S.A_Serviço de Endocrinologia · Vila Nova de Gaia, Portugal
  • Medical Practice SRL · Oradea, Romania
  • Başkent Üniversitesi Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi -Endokrinoloji · Adana /yüreği̇r, Turkey (Türkiye)
Show 18 removed
  • Zentrum fuer klinische Studien Suedbrandenburg GmbH · Elsterwerda, Germany
  • Békés Vármegyei Központi Kórház · Gyula, Hungary
  • Przychodnie Grudziadz Sp. z o. o. · Grudziądz, Poland
  • NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska · Bialystok, Poland
  • NZOZ Vita-Diabetica Malgorzata Buraczyk · Bialystok, Poland
  • Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski · Gorzów Wielkopolski, Poland
  • Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j. · Legnica, Poland
  • Serce Sp. z o.o. · Leszno, Poland
  • Centrum Terapii Wspolczesnej - J.M. Jasnorzewska S.K.A. · Lodz, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j. · Ruda Śląska, Poland
  • Hospital de Cascais · Alcabideche, Portugal
  • ULS Almada-Seixal E.P.E. - Hospital Garcia de Orta · Almada, Portugal
  • ULS De Braga, E.P.E. - Hospital de Braga · Braga, Portugal
  • ULS De São João, E.P.E. - Hospital de São João · Porto, Portugal
  • ULS De Matosinhos E.P.E.- Hospital Pedro Hispano · Senhora Da Hora, Matosinhos, Portugal
  • Hospital da Luz Arrabida, S.A. · Vila Nova de Gaia, Portugal
  • Medical Practice SRL · Oradea, Romania
  • Başkent Üniversitesi Adana-Endokrinoloji · Adana /yüreği̇r, Turkey (Türkiye)
Nov 10, 2026
Primary completion
Dec 12, 2028→Dec 19, 2028
Nov 10, 2026
Study completion
Jan 26, 2029→Dec 19, 2028
Nov 10, 2026
Enrollment
1000 (estimated)→985 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Active, not recruiting
    20 sites added, 18 sites removed
    Show 20 added (8 Poland, 6 Portugal, 2 India, 1 Germany, 1 Hungary, 1 Romania, 1 Turkey (Türkiye))
    • Zentrum für klinische Studien Südbrandenburg GmbH · Elsterwerda, Germany
    • Békés Vármegyei Központi Kórház · Gyula, Hungary
    • All India Institute of Medical Sciences (AIIMS), Raipur · Raipur, India
    • Osmania General Hospital · Hyderabad, India
    • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j. · Ruda Śląska, Poland
    • Serce Sp. z o.o. · Leszno, Poland
    • Przychodnie Grudziadz Sp. z o. o. · Grudziądz, Poland
    • Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j. · Legnica, Poland
    • Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski · Gorzów Wielkopolski, Poland
    • NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska · Bialystok, Poland
    • NZOZ Vita-Diabetica Malgorzata Buraczyk · Bialystok, Poland
    • Centrum Terapii Wspolczesnej - J.M. Jasnorzewska S.K.A. · Lodz, Poland
    • ULS Almada-Seixal E.P.E. - HGO_Serviço de Endocrinologia · Almada, Portugal
    • ULS De Braga, E.P.E. - Hospital de Braga_Centro Clínico Académico · Braga, Portugal
    • Hospital de Cascais_Serviço de Medicina Interna_Consultas Externas · Cascais, Portugal
    • ULS De São João, E.P.E. - Hospital de São João_Consulta Externa Endocrinologia · Porto, Portugal
    • ULS De Matosinhos, E.P.E - HPH_Serviço de Endocrinologia · Senhora Da Hora, Matosinhos, Portugal
    • Hospital da Luz Arrábida, S.A_Serviço de Endocrinologia · Vila Nova de Gaia, Portugal
    • Medical Practice SRL · Oradea, Romania
    • Başkent Üniversitesi Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi -Endokrinoloji · Adana /yüreği̇r, Turkey (Türkiye)
    Show 18 removed
    • Zentrum fuer klinische Studien Suedbrandenburg GmbH · Elsterwerda, Germany
    • Békés Vármegyei Központi Kórház · Gyula, Hungary
    • Przychodnie Grudziadz Sp. z o. o. · Grudziądz, Poland
    • NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska · Bialystok, Poland
    • NZOZ Vita-Diabetica Malgorzata Buraczyk · Bialystok, Poland
    • Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski · Gorzów Wielkopolski, Poland
    • Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j. · Legnica, Poland
    • Serce Sp. z o.o. · Leszno, Poland
    • Centrum Terapii Wspolczesnej - J.M. Jasnorzewska S.K.A. · Lodz, Poland
    • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j. · Ruda Śląska, Poland
    • Hospital de Cascais · Alcabideche, Portugal
    • ULS Almada-Seixal E.P.E. - Hospital Garcia de Orta · Almada, Portugal
    • ULS De Braga, E.P.E. - Hospital de Braga · Braga, Portugal
    • ULS De São João, E.P.E. - Hospital de São João · Porto, Portugal
    • ULS De Matosinhos E.P.E.- Hospital Pedro Hispano · Senhora Da Hora, Matosinhos, Portugal
    • Hospital da Luz Arrabida, S.A. · Vila Nova de Gaia, Portugal
    • Medical Practice SRL · Oradea, Romania
    • Başkent Üniversitesi Adana-Endokrinoloji · Adana /yüreği̇r, Turkey (Türkiye)
    Primary completion Dec 12, 2028→Dec 19, 2028
    Study completion Jan 26, 2029→Dec 19, 2028
    Enrollment 1000 (estimated)→985 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07400107
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
May 20, 2026
Primary completion
Dec 19, 2028 (estimated)
Completion
Dec 19, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion